Zydus Lifesciences Limited (NSEI: ZYDUSLIFE)
Health Care · Pharmaceuticals · IN
Rs1,120.00
-1.34% today · +13.3% 1Y
Zydus Lifesciences Limited (NSEI: ZYDUSLIFE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $11.68B and employs 29,980 people.
Over the last twelve months the share price has gained 13.3%, trading between 835.50 and 1.21K.
Tweenvest scores Zydus Lifesciences Limited across four factors: quality 79/100, value 40/100, growth 61/100, dividend 23/100. Its strongest factor is quality.
ZYDUSLIFE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.68B
- Revenue (TTM)
- $3.02B
- P/E
- 24.97
- EPS
- 44.86
- Dividend yield
- 0.09%
- Beta (5Y)
- 0.37
- 52-week high
- Rs1,205.00
- 52-week low
- Rs835.50
- Avg volume (3M)
- —
- Shares outstanding
- 997.50M
- Employees
- 29,980
- Next earnings
- —
About Zydus Lifesciences Limited
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
- ISIN
- INE010B01027
- Founded
- 1952
- Listed since
- Jul 1, 2002
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.